NEW YORK – There has been a keen interest in developing pan-cancer or tissue-agnostic biomarkers for cancer treatments in recent years, with many experts anticipating the field to shift from organ-based cancer treatments to ones that are based on molecular alterations. But a new study by researchers at Memorial Sloan Kettering Cancer Center questions whether certain mutations always behave the same way across tissue types.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.